Liquidia settles all pending litigation with United Therapeutics, agrees to USD 380.7 million net payment

Liquidia entered a global settlement with United Therapeutics that ends all pending litigation between the companies. Deal follows a Sept. 30, 2026 Delaware court ruling that two claims of United Therapeutics’ ’327 patent were valid and infringed. Liquidia agreed not to appeal. It filed a label supplement removing the PH-ILD indication for YUTREPIA. Financial terms include a net USD 175 million payment within 30 business days. Additional USD 145.4 million is due in early 2027. Liquidia will pay USD 60.3 million to resolve third-party interests tied to treprostinil injection antitrust litigation. Promotional support ends. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Liquidia Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-115672), on October 14,